Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors.

Karuna's lead product is KarXT xanomeline/trospium chloride. Designed to have antipsychotic properties without cholinergic side effects, the candidate combines xanomeline, an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and CHRM4, with trospium chloride, an antagonist of CHRM2 and CHRM3...